Real-Life Outcomes of Oral Provocation Testing with Alternative NSAIDs in NSAID Hypersensitivity
- 17 March 2026
- journal article
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 40-47
Abstract
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common causes of drug hypersensitivity reactions. Identifying safe alternative NSAIDs through oral provocation testing (OPT) is essential for clinical management. The 2025 World Allergy Organization (WAO) classification introduced updated phenotypes, highlighting the need for real-life data on tolerated alternative agents.Materials and methods:This retrospective study included 824 adults evaluated for suspected NSAID hypersensitivity between January 2020 and September 2025. Patients were reclassified according to the 2025 WAO criteria. Demographic characteristics, comorbid allergic diseases, culprit drugs, laboratory parameters, and outcomes of OPT with alternative NSAIDs were analyzed.Results:The mean age was 44.7 ± 13.2 years, and 65.5% of patients were female. According to the 2025 WAO classification, 48.8% had NSAID-exacerbated cutaneous disease (NECD), 32.2% NSAID-induced urticaria/angioedema (NIUA), and 11.2% single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA). Among 704 patients undergoing OPT, tolerance rates were high for meloxicam (96%), nimesulide (97%), and celecoxib (98.6%). The distribution of asthma, rhinitis, urticaria/angioedema, chronic sinusitis, and nasal polyps differed significantly among WAO phenotypes (p < 0.05), whereas tolerance to alternative NSAIDs did not differ between groups (p > 0.05).Conclusion:Meloxicam, nimesulide, and celecoxib are well tolerated in most patients with NSAID hypersensitivity. The 2025 WAO classification improves phenotypic stratification, while OPT remains a reliable method for identifying safe alternative NSAIDs in real-life practice.Keywords
This publication has 21 references indexed in Scilit:
- Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO StatementWorld Allergy Organization Journal, 2025
- Guiding Drug Provocation Testing for Ibuprofen Hypersensitivity in a Pediatric Population: Development of the I3A Risk-Stratification ToolThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- EAACI/ENDA position paper on drug provocation testingAllergy, 2023
- Safety and outcomes of “at-home self-provocation tests” in patients with mild nonsteroidal anti-inflammatory drug–induced urticaria/angioedemaAnnals of Allergy, Asthma & Immunology, 2023
- Safety, Outcomes, and Recommendations for Two-Step Outpatient Nonsteroidal Anti-Inflammatory Drug ChallengesThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organsScientific Reports, 2018
- Frequency of self-reported drug allergyAnnals of Allergy, Asthma & Immunology, 2017
- Evaluation of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs according to the latest classificationAllergy, 2015
- Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti‐inflammatory drugsAllergy, 2013
- Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literatureArchives of Dermatological Research, 2007